Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
measles and rubella vaccine
- Development stage
- Phase 2
- Lead developer
- Micron Biomedical
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Transdermal, Subcutaneous
01
Overview
The measles rubella vaccine (MRV) is a bivalent combination vaccine containing live-attenuated strains of the measles and rubella viruses. It is designed to elicit a protective immune response, characterized by the production of specific IgG antibodies and neutralizing titers against both pathogens. While traditionally administered via subcutaneous injection, recent development efforts by Micron Biomedical have focused on a microneedle patch (MRV-MNP) delivery system. This technology aims to provide a stable, easy-to-administer, and less invasive alternative to needle-and-syringe vaccinations, particularly for use in infants and toddlers in low-resource settings. The MRV-MNP is currently being evaluated in Phase 1/2 clinical trials to assess its safety and immunogenicity compared to standard subcutaneous administration.
- Other names
- MRVMR vaccineMeasles-Rubella Vaccine
02
Targets
B-cell receptors specific for measles H/F and rubella E1/E2 antigensCD46 (CD46 Molecule)PVRL4 (Nectin cell adhesion molecule 4)RNA-sensing pattern recognition receptor
Beyond the preview
Go deeper on measles and rubella vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on measles and rubella vaccine.